Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients

Janna C. Minehart, Christopher Catania, Linda Perry, Mary Ellen Martin, Jacqueline Smith, Shannon R. McCurdy, Keith W. Pratz, Selina M. Luger, Colleen Timlin, Alexander E. Perl, Mindy Schuster, David L Porter, Alison W. Loren, Elizabeth O. Hexner, Noelle V Frey

Blood (2021) 138 (Supplement 1): 2888.

https://doi.org/10.1182/blood-2021-153920

Published: 2021

Journal Articles

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Craig W. Freyer, PharmD, Alex Ganetsky, PharmD, Colleen Timlin, PharmD, Daria V. Babushok, MD PhD, Noelle V. Frey, MD, Saar I. Gill, MD PhD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, Selina Luger, MD, Jacqueline Smith, MSN, CRNP, Edward Stadtmauer, David L. Porter, MD

Blood (2018) 132 (Supplement 1): 5696.

https://doi.org/10.1182/blood-2018-99-111550

Published: 2018

Journal Articles

Oral Vancomycin Is Highly Effective in Preventing Clostridium Difficile infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Alex Ganetsky, PharmD, BCOP, Jennifer H Han, MD MSCE, Mitchell E Hughes, PharmD, Daria V. Babushok, MD PhD, Noelle V Frey, MD, Saar I Gill, MBBS, PhD, Elizabeth Hexner, MD, Alison Wakoff Loren, MD MS, Selina Luger, MD, James K Mangan, MD PhD, Jacqueline Smith, CRNP, Edward A. Stadtmauer, MD, Craig W. Freyer, PharmD, BCOP, Cheryl Gilmar, MT, David L Porter, MD

Blood (2016) 128 (22): 2225.

https://doi.org/10.1182/blood.V128.22.2225.2225

Published: 2016

Journal Articles

Tocilizumab Is Highly Active for Severe Steroid-Refractory Acute Graft-Versus-Host Disease of the Gastrointestinal Tract

Alex Ganetsky, PharmD, BCOP, Noelle V Frey, MD, Alison W Loren, MD MS, Elizabeth O. Hexner, MD, James K Mangan, MD PhD, Saar I Gill, MBBS, PhD, Selina Luger, MD, Adam D. Cohen, MD, Daria V Babushok, MDPhD, Edward A Stadtmauer, MD, Jacqueline Smith, CRNP, William R. Drobyski, MD, Sarah K Kraus, PharmD, Colleen Timlin, PharmD, BCOP, David L. Porter, MD

Blood (2016) 128 (22): 2245.

https://doi.org/10.1182/blood.V128.22.2245.2245

Published: 2016

Journal Articles

Allogeneic Stem Cell Transplantation in Patients ≥70 Years Old

Christopher C Walling, BS, Pamela A Shaw, PhD, Noelle V Frey, MD, Saar I Gill, MBBS, PhD, Elizabeth O. Hexner, MD, Alison W Loren, MD MS, Selina Luger, MD, James K Mangan, MD PhD, Mary Ellen Martin, MD, Jacqueline Smith, CRNP, Edward A. Stadtmauer, MD, David L. Porter, MD

Blood (2016) 128 (22): 2309.

https://doi.org/10.1182/blood.V128.22.2309.2309

Published: 2016

Journal Articles

Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival

Anita J. Kumar, MDMS, Pavel Vassilev, BS, Alison W. Loren, MDMS, Selina M. Luger, MD, Ran Reshef, MD, Saar I. Gill, MD PhD, Jacqueline Smith, CRNP, Steven C. Goldstein, MD, Elizabeth Hexner, MD, Edward A. Stadtmauer, MD, David Porter, MD, Noelle V. Frey, MDMS

Blood (2014) 124 (21): 3946.

https://doi.org/10.1182/blood.V124.21.3946.3946

Published: 2014

Journal Articles

Clofarabine Busulfan Conditioning Improves Outcomes in Patients with Active Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplant

Alexis Zebrowski, BA, Alexandra Hanlon, PhD, James Mangan, MD PhD, Jennifer Pinto-Martin, PhD MPH, Selina M. Luger, MD, Alison W. Loren, MD, Elizabeth O Hexner, MD, Ran Reshef, MD, Saar I. Gill, MD PhD, Jacqueline Smith, CRNP, Edward A. Stadtmauer, MD, David Porter, MD, Noelle V. Frey, MDMS

Blood (2014) 124 (21): 1239.

https://doi.org/10.1182/blood.V124.21.1239.1239

Published: 2014

Journal Articles

Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations

Warren Fiskus, BSc, PhD, Catherine C. Smith, MD, Jacqueline Smith, MS, Scott C. Wise, MS, Elisabeth Lasater, PhD, Lauren E. Damon, Sara Salerno, BS, Allan Fleming, MD, Ruben Reyes, MD, Siddhartha Ganguly, MD, Mark S. Berger, MD, Tom J. Rutkoski, Ph.D, Joseph McGuirk, DO, Neil Shah, MD, PhD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 2611.

https://doi.org/10.1182/blood.V118.21.2611.2611

Published: 2011

Journal Articles

Treatment with β-Catenin Antagonist BC2059 Exerts Single Agent Efficacy and Exerts Improved Activity with Tyrosine Kinase Inhibitor (TKI) or Pan-Histone Deacetylase (HDAC) Inhibitor Against Human CML and Myeloproliferative Neoplasm (MPN) Progenitor Cells

Warren Fiskus, PhD, Jacqueline Smith, MS, Uma Mudunuru, MS, Stacey Hembruff, MS, Ruben Reyes, MD, Sunil Abhyankar, MD, Joseph McGuirk, DO, Omar S. Aljitawi, MD, Siddhartha Ganguly, MD, Stephen K. Horrigan, PhD, Sunil Sharma, MD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 65.

https://doi.org/10.1182/blood.V118.21.65.65

Published: 2011

Journal Articles

Whole Blood Donor Chimerism At Day 30 After Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation Predicts Disease Relapse, and Is Strongly Associated with Pretransplant Lymphodepletion

Ran Reshef, MD, Rosemarie Mick, MS, Pavel Vassilev, BS, Jacqueline Smith, CRNP, Elizabeth Hexner, MD, Alison W. Loren, MD, Noelle V. Frey, MD, Steven C. Goldstein, MD, Edward A. Stadtmauer, MD, Selina M. Luger, MD, David L. Porter, MD

Blood (2011) 118 (21): 1939.

https://doi.org/10.1182/blood.V118.21.1939.1939

Published: 2011

Journal Articles

Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist – Final Results of a Phase I/II Study

Ran Reshef, MD, Selina M. Luger, MD, Elizabeth O. Hexner, MD, Alison W. Loren, MD, Noelle V. Frey, MD, Steven C. Goldstein, MD, Sunita D. Nasta, MD, Edward A. Stadtmauer, MD, Jacqueline Smith, CRNP, Rosemarie Mick, MS, Daniel F. Heitjan, PhD, James A. Hoxie, MD, Stephen G. Emerson, MD, PhD, Robert H. Vonderheide, MD, PhD, David L. Porter, MD

Blood (2011) 118 (21): 1011.

https://doi.org/10.1182/blood.V118.21.1011.1011

Published: 2011

Journal Articles

Reduced Intensity Conditioning with Fludarabine/Busulfan 6.4mg/Kg Results In High Donor Chimerism and Low Toxicity In Both Related and Unrelated Allo-SCT for Hematologic Malignancies.

Steven C Goldstein, MD, Selina M. Luger, MD, Noelle Frey, MD, Alexander Perl, MD, Edward A Stadtmauer, MD, Donald Tsai, MD, Alison Loren, MD, Sunita Nasta, MD, Elizabeth Hexner, MD, Ran Reshef, MD, Jacqueline Smith, CRNP, Joanne Hinkle, Pavel Vassilev, BS, Michael J Vozniak, PharmD, David L. Porter, MD

Blood (2010) 116 (21): 4519.

https://doi.org/10.1182/blood.V116.21.4519.4519

Published: 2010

Journal Articles

Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL).

Vikram R Paralkar, MD, Sunita Dwivedy Nasta, MD, Kelly Morrissey, MD, Jacqueline Smith, MSN, CRNP, Pavel Vassilev, BS, Mary Ellen Martin, MD, Steven C Goldstein, MD, Alison Loren, MD, MPH, Alain H Rook, MD, Ellen J Kim, MD, David L Porter, MD

Blood (2010) 116 (21): 4574.

https://doi.org/10.1182/blood.V116.21.4574.4574

Published: 2010

Journal Articles

Prevention of Graft-Versus-Host Disease by Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist

Ran Reshef, MD, Selina M. Luger, MD, Alison W. Loren, MD, Noelle V. Frey, MD, Steven C. Goldstein, MD, Elizabeth O. Hexner, MD, Edward A. Stadtmauer, MD, Jacqueline Smith, CRNP, Rosemarie Mick, MS, Daniel F. Heitjan, PhD, Susan E. Shetzline, PhD, Gwenn-ael H. Danet-Desnoyers, PhD, Stephen G. Emerson, MD, PhD, James A. Hoxie, MD, Robert H. Vonderheide, MD, PhD, David L. Porter, MD

Blood (2010) 116 (21): 673.

https://doi.org/10.1182/blood.V116.21.673.673

Published: 2010

Journal Articles

Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.

Alison Rager, MD, Steven C. Goldstein, MD, Noelle Frey, MD, Jennifer Davis, PharmD, Michael Vozniak, PharmD, Jacqueline Smith, Elizabeth Hexner, MD, Alison Wakoff Loren, MD, MS, Selina Luger, MD, Alexander Perl, MD, Ran Reshef, MD, Donald E Tsai, MD, PhD, Edward A. Stadtmauer, MD, David Porter, MD

Blood (2009) 114 (22): 4643.

https://doi.org/10.1182/blood.V114.22.4643.4643

Published: 2009

Journal Articles

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

Steven C Goldstein, MD, Bruce Levine, PhD, Jacqueline Smith, MSN, CRNP, Joanne Hinkle, RN, BSN, OCN, Selina Luger, MD, Alexander Perl, MD, Alison Loren, MD, Noelle Frey, MD, Edward Stadtmauer, MD, Daniel Schullery, PhD, Jean Boyer, PhD, Dennis L. Confer, MD, David Porter, MD, Carl H. June, MD

Blood (2008) 112 (11): 468.

https://doi.org/10.1182/blood.V112.11.468.468

Published: 2008

NARROW

Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Oral Vancomycin Is Highly Effective in Preventing Clostridium Difficile infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Tocilizumab Is Highly Active for Severe Steroid-Refractory Acute Graft-Versus-Host Disease of the Gastrointestinal Tract

Allogeneic Stem Cell Transplantation in Patients ≥70 Years Old

Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival

Clofarabine Busulfan Conditioning Improves Outcomes in Patients with Active Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplant

Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations

Treatment with β-Catenin Antagonist BC2059 Exerts Single Agent Efficacy and Exerts Improved Activity with Tyrosine Kinase Inhibitor (TKI) or Pan-Histone Deacetylase (HDAC) Inhibitor Against Human CML and Myeloproliferative Neoplasm (MPN) Progenitor Cells

Whole Blood Donor Chimerism At Day 30 After Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation Predicts Disease Relapse, and Is Strongly Associated with Pretransplant Lymphodepletion

Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist – Final Results of a Phase I/II Study

Reduced Intensity Conditioning with Fludarabine/Busulfan 6.4mg/Kg Results In High Donor Chimerism and Low Toxicity In Both Related and Unrelated Allo-SCT for Hematologic Malignancies.

Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL).

Prevention of Graft-Versus-Host Disease by Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist

Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only